Synergistic actions of enalapril and tempol during chronic angiotensin II-induced hypertension

Ahmed Abdelrazik Elmarakby, Jan M. Williams, John D. Imig, Jennifer S. Pollock, David M. Pollock

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Experiments were designed to test the hypothesis that antioxidant treatment would increase the anti-hypertensive actions of endogenous kinins during angiotensin converting enzyme (ACE) inhibition. Four groups of rats, all given angiotensin II (Ang II) for 2 weeks, were studied: 1) control, 2) enalapril, 3) tempol or 4) both tempol and enalapril. Ang II significantly increased systolic blood pressure (BP) when compared with the baseline (170 ± 8 vs. 128 ± 4 mm Hg, P < 0.05). Neither enalapril nor tempol alone was able to attenuate the elevation in BP (165 ± 7 and 164 ± 6 mm Hg, respectively). In contrast, combined administration of tempol and enalapril prevented the increase in BP (137 ± 5 mm Hg). Plasma 8-isoprostane increased in Ang II-infused rats when compared with control untreated rats (69 ± 14 vs. 23 ± 0.5 pg/ml, P < 0.05). Tempol alone or tempol plus enalapril significantly attenuated the increase in plasma 8-isoprostane (29 ± 6 and 34 ± 7 pg/ml, respectively). In additional experiments, we used the bradykinin B2 antagonist, icatibant to determine if increased B2 receptor contributes to the anti-hypertensive effect of combined tempol and enalapril in Ang II-infused rats. Icatibant decreased the ability of this combination to lower arterial pressure. Additionally, a significant increase in B1 receptor protein expression in renal cortex of Ang II-infused rats was observed compared to control suggesting that bradykinin receptor activation could account for the effect of enalapril to enhance the actions of tempol. These data support the hypothesis that combined reduction of superoxide along with enhanced endogenous kinins may facilitate blood pressure lowering in Ang II hypertension.

Original languageEnglish (US)
Pages (from-to)144-151
Number of pages8
JournalVascular Pharmacology
Volume46
Issue number2
DOIs
StatePublished - Feb 1 2007

Fingerprint

Enalapril
Angiotensin II
Hypertension
8-epi-prostaglandin F2alpha
Blood Pressure
Kinins
Antihypertensive Agents
Bradykinin Receptors
tempol
Peptidyl-Dipeptidase A
Superoxides
Arterial Pressure
Antioxidants
Kidney

Keywords

  • 8-isoprostane
  • Angiotensin converting enzyme inhibitors
  • Arterial pressure
  • Oxidative stress
  • Rats
  • Superoxide

ASJC Scopus subject areas

  • Pharmacology

Cite this

Synergistic actions of enalapril and tempol during chronic angiotensin II-induced hypertension. / Elmarakby, Ahmed Abdelrazik; Williams, Jan M.; Imig, John D.; Pollock, Jennifer S.; Pollock, David M.

In: Vascular Pharmacology, Vol. 46, No. 2, 01.02.2007, p. 144-151.

Research output: Contribution to journalArticle

Elmarakby, Ahmed Abdelrazik ; Williams, Jan M. ; Imig, John D. ; Pollock, Jennifer S. ; Pollock, David M. / Synergistic actions of enalapril and tempol during chronic angiotensin II-induced hypertension. In: Vascular Pharmacology. 2007 ; Vol. 46, No. 2. pp. 144-151.
@article{b71a191dc85349b0b8e368a9f8129325,
title = "Synergistic actions of enalapril and tempol during chronic angiotensin II-induced hypertension",
abstract = "Experiments were designed to test the hypothesis that antioxidant treatment would increase the anti-hypertensive actions of endogenous kinins during angiotensin converting enzyme (ACE) inhibition. Four groups of rats, all given angiotensin II (Ang II) for 2 weeks, were studied: 1) control, 2) enalapril, 3) tempol or 4) both tempol and enalapril. Ang II significantly increased systolic blood pressure (BP) when compared with the baseline (170 ± 8 vs. 128 ± 4 mm Hg, P < 0.05). Neither enalapril nor tempol alone was able to attenuate the elevation in BP (165 ± 7 and 164 ± 6 mm Hg, respectively). In contrast, combined administration of tempol and enalapril prevented the increase in BP (137 ± 5 mm Hg). Plasma 8-isoprostane increased in Ang II-infused rats when compared with control untreated rats (69 ± 14 vs. 23 ± 0.5 pg/ml, P < 0.05). Tempol alone or tempol plus enalapril significantly attenuated the increase in plasma 8-isoprostane (29 ± 6 and 34 ± 7 pg/ml, respectively). In additional experiments, we used the bradykinin B2 antagonist, icatibant to determine if increased B2 receptor contributes to the anti-hypertensive effect of combined tempol and enalapril in Ang II-infused rats. Icatibant decreased the ability of this combination to lower arterial pressure. Additionally, a significant increase in B1 receptor protein expression in renal cortex of Ang II-infused rats was observed compared to control suggesting that bradykinin receptor activation could account for the effect of enalapril to enhance the actions of tempol. These data support the hypothesis that combined reduction of superoxide along with enhanced endogenous kinins may facilitate blood pressure lowering in Ang II hypertension.",
keywords = "8-isoprostane, Angiotensin converting enzyme inhibitors, Arterial pressure, Oxidative stress, Rats, Superoxide",
author = "Elmarakby, {Ahmed Abdelrazik} and Williams, {Jan M.} and Imig, {John D.} and Pollock, {Jennifer S.} and Pollock, {David M.}",
year = "2007",
month = "2",
day = "1",
doi = "10.1016/j.vph.2006.09.004",
language = "English (US)",
volume = "46",
pages = "144--151",
journal = "Vascular Pharmacology",
issn = "1537-1891",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Synergistic actions of enalapril and tempol during chronic angiotensin II-induced hypertension

AU - Elmarakby, Ahmed Abdelrazik

AU - Williams, Jan M.

AU - Imig, John D.

AU - Pollock, Jennifer S.

AU - Pollock, David M.

PY - 2007/2/1

Y1 - 2007/2/1

N2 - Experiments were designed to test the hypothesis that antioxidant treatment would increase the anti-hypertensive actions of endogenous kinins during angiotensin converting enzyme (ACE) inhibition. Four groups of rats, all given angiotensin II (Ang II) for 2 weeks, were studied: 1) control, 2) enalapril, 3) tempol or 4) both tempol and enalapril. Ang II significantly increased systolic blood pressure (BP) when compared with the baseline (170 ± 8 vs. 128 ± 4 mm Hg, P < 0.05). Neither enalapril nor tempol alone was able to attenuate the elevation in BP (165 ± 7 and 164 ± 6 mm Hg, respectively). In contrast, combined administration of tempol and enalapril prevented the increase in BP (137 ± 5 mm Hg). Plasma 8-isoprostane increased in Ang II-infused rats when compared with control untreated rats (69 ± 14 vs. 23 ± 0.5 pg/ml, P < 0.05). Tempol alone or tempol plus enalapril significantly attenuated the increase in plasma 8-isoprostane (29 ± 6 and 34 ± 7 pg/ml, respectively). In additional experiments, we used the bradykinin B2 antagonist, icatibant to determine if increased B2 receptor contributes to the anti-hypertensive effect of combined tempol and enalapril in Ang II-infused rats. Icatibant decreased the ability of this combination to lower arterial pressure. Additionally, a significant increase in B1 receptor protein expression in renal cortex of Ang II-infused rats was observed compared to control suggesting that bradykinin receptor activation could account for the effect of enalapril to enhance the actions of tempol. These data support the hypothesis that combined reduction of superoxide along with enhanced endogenous kinins may facilitate blood pressure lowering in Ang II hypertension.

AB - Experiments were designed to test the hypothesis that antioxidant treatment would increase the anti-hypertensive actions of endogenous kinins during angiotensin converting enzyme (ACE) inhibition. Four groups of rats, all given angiotensin II (Ang II) for 2 weeks, were studied: 1) control, 2) enalapril, 3) tempol or 4) both tempol and enalapril. Ang II significantly increased systolic blood pressure (BP) when compared with the baseline (170 ± 8 vs. 128 ± 4 mm Hg, P < 0.05). Neither enalapril nor tempol alone was able to attenuate the elevation in BP (165 ± 7 and 164 ± 6 mm Hg, respectively). In contrast, combined administration of tempol and enalapril prevented the increase in BP (137 ± 5 mm Hg). Plasma 8-isoprostane increased in Ang II-infused rats when compared with control untreated rats (69 ± 14 vs. 23 ± 0.5 pg/ml, P < 0.05). Tempol alone or tempol plus enalapril significantly attenuated the increase in plasma 8-isoprostane (29 ± 6 and 34 ± 7 pg/ml, respectively). In additional experiments, we used the bradykinin B2 antagonist, icatibant to determine if increased B2 receptor contributes to the anti-hypertensive effect of combined tempol and enalapril in Ang II-infused rats. Icatibant decreased the ability of this combination to lower arterial pressure. Additionally, a significant increase in B1 receptor protein expression in renal cortex of Ang II-infused rats was observed compared to control suggesting that bradykinin receptor activation could account for the effect of enalapril to enhance the actions of tempol. These data support the hypothesis that combined reduction of superoxide along with enhanced endogenous kinins may facilitate blood pressure lowering in Ang II hypertension.

KW - 8-isoprostane

KW - Angiotensin converting enzyme inhibitors

KW - Arterial pressure

KW - Oxidative stress

KW - Rats

KW - Superoxide

UR - http://www.scopus.com/inward/record.url?scp=33845561904&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845561904&partnerID=8YFLogxK

U2 - 10.1016/j.vph.2006.09.004

DO - 10.1016/j.vph.2006.09.004

M3 - Article

C2 - 17112788

AN - SCOPUS:33845561904

VL - 46

SP - 144

EP - 151

JO - Vascular Pharmacology

JF - Vascular Pharmacology

SN - 1537-1891

IS - 2

ER -